Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: A review of medication profiles in 435 Canadian outpatients

Journal of Clinical Psychiatry

Volumn 71, Issue 5, 2010, Pages 566-573

  Procyshyn, Ric M ^a,b   Honer, William G ^a,b   Wu, Tony K Y ^b   Ko, Rebecca W Y ^b   McIsaac, Sean A ^b   Young, Allan H ^b   Johnson, Joy L ^b   Barr, Alasdair M ^a,b  

^a British Columbia Mental Health and Addictions Research Institute   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BENZODIAZEPINE DERIVATIVE; CLOZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AGE DISTRIBUTION; ARTICLE; BIPOLAR DISORDER; CANADA; COHORT ANALYSIS; COMMUNITY MENTAL HEALTH; DEMOGRAPHY; DRUG UTILIZATION; FEMALE; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAL RECORD; MONOTHERAPY; MOOD DISORDER; OUTPATIENT; POLYPHARMACY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEX DIFFERENCE; TREATMENT DURATION;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BRITISH COLUMBIA; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MEDICAL AUDIT; MEDICATION ERRORS; MENTAL DISORDERS; MIDDLE AGED; OUTPATIENTS; POLYPHARMACY; PREVALENCE; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 77952633076     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04912gre     Document Type: Article

References (51)

1. Moore TA, Covell NH, Essock SM, et al. Real-world antipsychotic treatment practices. Psychiatr Clin North Am. 2007;30(3):401-416.
2. Ereshefsky L. Pharmacological and pharmacokinetic considerations in choosing an antipsychotic. J Clin Psychiatry. 1999;60(suppl:10):20-30. (Pubitemid 29237172)
3. Fourrier A, Gasquet I, Allicar MP, et al. Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists. Br J Clin Pharmacol. 2000;49(1):80-86. (Pubitemid 30050490)
4. Ito T, Kubota Y, Sato M. A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia. Psychiatry Clin Neurosci. 1999;53(6):667-672.
5. Keks NA, Altson K, Hope J, et al. Use of antipsychotics and adjunctive medications by an inner urban community psychiatric service. Aust N Z J Psychiatry. 1999;33(6):896-901. (Pubitemid 30015857)
6. Meltzer HY, Kostakoglu AE. Combining antipsychotics: is there evidence for efficacy? Psychiatric Times. 2000;17:25-32.
7. Rittmannsberger H, Meise U, Schauflinger K, et al. Polypharmacy in psychiatric treatment patterns of psychotropic drug use in Austrian psychiatric clinics. Eur Psychiatry. 1999;14(1):33-40.
8. Stahl SM. Antipsychotic polypharmacy, pt 1: therapeutic option or dirty little secret? J Clin Psychiatry. 1999;60(7):425-426.
9. Stahl SM. Antipsychotic polypharmacy, pt 2: tips on use and misuse. J Clin Psychiatry. 1999;60(8):506-507.
10. Tapp A, Wood AE, Secrest L, et al. Combination antipsychotic therapy in clinical practice. Psychiatr Serv. 2003;54(1):55-59. (Pubitemid 36043847)
11. Ganguly R, Katzan JA, Miller LS, et al. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry. 2004;65(10):1377-1388.
12. Ito H, Koyama A, Higuchi T. Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. Br J Psychiatry. 2005;187:243-247.
13. Biancosino B, Barbui C, Marmai L, et al. Determinants of antipsychotic polypharmacy in psychiatric inpatients; a prospective study. Int Clin Psychopharmacol. 2005;20(6):305-309. (Pubitemid 41475319)
14. Brunot A, Lachaux B, Sontag H, et al. Pharmco-epidemiological study on antipsychotic drug prescription in French psychiatry: patient characteristics, antipsychotic treatment, and care management for schizophrenia. Encephale. 2002;28(2):129-138 [French].
15. Centorrino F, Eakin M, Bahk WM, et al. Inpatient antipsychotic drug use in 1998, 1993, and 1989. Am J Psychiatry. 2002;159(11):1932-1935.
16. Yip KC, Ungvari GS, Kin CH, et al. A survey of antipsychotic treatment for schizophrenia in Hong Kong. Chin Med J (Engl). 1997;110(10):792-796. (Pubitemid 27443738)
17. Covell NH, Jackson CT, Evans AC, et al. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull. 2002;28(1):17-29.
18. Frangou S, Lewis M. Atypical antipsychotics in ordinary clinical practice: a pharmaco-epidemiologic survey in a south London service. Eur Psychiatry. 2000;15(3):220-226. (Pubitemid 30350559)
19. Leslie DL, Rosenheck RA. Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system. Med Care. 2001;39(9):923-933.
20. Procyshyn RM, Kennedy NB, Tse G, et al. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry. 2001;46(4):334-339. (Pubitemid 32531565)
21. Procyshyn RM, Thompson B. Patterns of antipsychotic utilization in a tertiary care psychiatric institution. Pharmacopsychiatry. 2004;37(1):12-17. (Pubitemid 38230735)
22. Wang PS, West JC, Tanielian T, et al. Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders. Schizophr Bull. 2000;26(2):451-457. (Pubitemid 30423221)
23. Weissman EM. Antipsychotic prescribing practices in the Veterans Healthcare Administration-New York, metropolitan region. Schizophr Bull. 2002;28(1):31-42.
24. Kogut SJ, Yam F, Dufresne R. Prescribing of antipsychotic medication in a Medicaid population: use of polytherapy and off-label dosages. J Manag Care Pharm. 2005;11(1):17-24.
25. Patrick V, Schleifer SJ, Nurenberg JR, et al. An initiative to curtail the use of antipsychotic polypharmacy in a state psychiatric hospital. Psychiatr Serv. 2006;57(1):21-23. (Pubitemid 43053830)
26. Faries D, Ascher-Svanum H, Zhu B, et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry. 2005;5:26.
27. Kreyenbuhl J, Valenstein M, McCarthy JF, et al. Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophr Res. 2006;84(1):90-99. (Pubitemid 43732483)
28. Clark RE, Bartels SJ, Mellman TA, et al. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implication for state mental health policy. Schizophr Bull. 2002;28(1):75-84.
29. Canales PL, Olsen J, Miller AL, et al. Role of antipsychotic polypharmacotherapy in the treatment of schizophrenia. CNS Drugs. 1999;12(3):179-188. (Pubitemid 29446503)
30. World Health Organization. Collaborating Center for Drug Statistics Methodology. /Definition and general considerations. http://www.whocc.no/ddd/ definition-and-general-considera/Accessed July 22, 2008.
31. Barbui C, Nosè M, Mazzi MA, et al. Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. Int Clin Psychopharmacol. 2006;21(6):355-362. (Pubitemid 44498277)
32. Barbui C, Biancosino B, Esposito E, et al. Factors associated with antipsychotic dosing in psychiatric inpatients: a prospective study. Int Clin Psychopharmacol. 2007;22(4):221-225. (Pubitemid 46801945)
33. McEvoy JP, Scheifler PL, Frances A. The Expert Consensus Guidelines Series: Treatment of Schizophrenia 1999. J Clin Psychiatry. 1999; 60(suppl 11):1-80.
34. Gilmer TP, Dolder CR, Folsom DP, et al. Antipsychotic polypharmacy trends among medical beneficiaries with schizophrenia in San Diego County, 1999-2004. Psychiatr Serv. 2007;58(7):1007-1010.
35. Morrato EH, Dodd S, Oderda G, et al. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003. Clin Ther. 2007;29(1):183-195.
36. Stahl SM, Grady MM. High-cost use of second-generation antipsychotics under California's Medicaid Program. Psychiatr Serv. 2006;57(1):127-129.
37. Tempier RP, Pawliuk NH. Conventional, atypical, and combination antipsychotic prescriptions: a 2-year comparison. J Clin Psychiatry. 2003;64(6):673-679. (Pubitemid 36750145)
38. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia: a review of efficacy and risks of current combinations. Acta Psychiatr Scand. 2002;106(5):323-330. (Pubitemid 35176874)
39. Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs. 2004;64(7):701-723. (Pubitemid 38471372)
40. Abdelmawla H, Mitchell AJ. Sudden cardiac death and antipsychotics, pt 1: risk factors and mechanisms. Adv Psychiatr Treat. 2006;12:35-44. (Pubitemid 43091931)
41. Waddington JL, Youssef JA, Kinsella A. Mortality in schizophrenia: antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry. 1998;173:325-329.
42. Kreyenbuhl JA, Valensein M, McCarthy JF, et al. Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. Psychiatr Serv. 2007;58(4):489-495.
43. Ananth J, Parameswaran S, Gunatilake S. Antipsychotic polypharmacy. Curr Pharm Des. 2004;10(18):2231-2238.
44. Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case not review. J Clin Psychiatry. 2003;64(1):30-34. (Pubitemid 36182226)
45. Tranulis C, Skalli L, Lalonde P, et al. Benefits and risks of antipsychotic polypharmacy: an evidenced-based review of the literature. Drug Saf. 2008;31(1):7-20.
46. Anil Yaǧcioǧlu AE, Kivircik BB, Turgut TI, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry. 2005;66(1):63-72.
47. Josiassen RC, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2005;162(1):130-136. (Pubitemid 40095682)
48. Honer WG, Thornton AE, Chen EYH, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med. 2006;354(5):472-482.
49. Shiloh R, Zemishlany A, Aizenberyg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. Br J Psychiatry. 1997;171:569-573.
50. Centorrino F, Goren JL, Hennen J, et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case control study of risk versus benefits. Am J Psychiatry. 2004;161(4):700-706. (Pubitemid 38445515)
51. Joukamaa M, Heliovaara M, Knekt P, et al. Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry. 2006;188:122-127.